Another issue could be a substantially higher prevalence of APOE e4 + compared to e4−in our aMCI-AD sample (45 (72.6%) vs 16 (25.8%) individuals, respectively), which is not surprising given that the APOE e4 allele is the strongest genetic risk factor for late-onset AD [24]. Here, APOE is linked to Alzheimer disease.